Effect of polycan, a β glucan originating from Aureobasidium, on a high fat diet induced hyperlipemic hamster model

Abstract

The aim of the present study was to analyze the effect of polycan, a β-glucan originating from Aureobasidium, on high-fat diet (HFD)-induced hyperlipemia and hepatic damage. A total of 30 hamsters were divided into 6 groups based on their body weight following acclimatization: control, sham, simvastatin (SIMVA) and 3 Polycan groups. In the polycan groups, Polycan, at three concentrations (31.25, 62.5 and 125 mg/kg), was administered orally once a day for 56 days, in addition to the HFD. On the day of sacrifice, changes in the body weight, food consumption, liver weight and serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride and total cholesterol (T-CHOL) were observed, as well as changes to the liver and aorta (thoracic and abdominal) histopathology and histomorphometry. The results from the polycan groups were compared with a SIMVA 10 mg/kg oral treatment group, in addition to the sham and vehicle control groups. After the HFD-induced hyperlipidemic hamsters were administered Polycan, there was no significant change in their body weight and food consumption when compared with the hamsters in the vehicle control group. However, the serum levels of AST, ALT, triglyceride, T-CHOL and LDL were significantly reduced in a dose-dependent manner when compared with the vehicle control group (P<0.05). Furthermore, the levels of liver steatosis and arteriosclerosis in the abdominal and thoracic aorta were significantly decreased in a dose-dependent manner (P<0.01). In the SIMVA-treated group, body weight (P<0.05), the serum level of lipids (triglyceride, T-CHOL and LDL; P<0.01) and the level of arteriosclerosis (P<0.01) were significantly reduced when compared with the vehicle control group. However, liver weight and the serum levels of AST, ALT, and liver steatosis increased when compared with the vehicle control group. Based on these results, it was concluded that polycan exerts a favorable effect in decreasing HFD-induced hyperlipemia and associated atherosclerosis, with relatively good protective effects on liver damage.